N
Google TrendMICHAEL OLISE (500+) — Transfer Rumors: Liverpool Handed Olise Boost; Man Utd Battle Real Madrid for McTominay
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:michael olise500+bank of america fine1000+club brugge200+rb leipzig200+anthony gordon500+mid atlantic ridge earthquakes500+montez sweat2000+rob lowe1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA Approves MRD-Guided U" (30 stories)

Top Headline Story

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Lead StoryBioSpacegeneral
Sep 22

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPM194My1kak1xTVNSMnR3S2RwdzhEaHFGY2pDankyWmN2bExMRnZnbjB1WGFRWFg2TlhWaXdSVktFVUxIdFg3cUdONkYxeXp4ZkJyOU9lT01uR1BHWGpQR2dxNzBhM3JkV0hWVkI3dWsxMmp5eE5JM1BMdkFzOEZHcEZCdVY0bDFTZWR2eTdsa2RYQjU5T3I4QWhMekNrT0NPckMxak5aUkV6WUxnNHhTd090U2h6T2JnTEdnS3ZGTVdib1p1cTI2ZVFLSS02Nm1IRUhVLWZyeGttLTRBNzUzVg?oc=5" target="_blank">Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+17m ago

michael olise

Transfer Rumors: Liverpool Handed Olise Boost; Man Utd Battle Real Madrid for McTominay

Filter stories
1000+17m ago

bank of america fine

Bank of America fined $1.2 billion over money-laundering violations

Filter stories
200+17m ago

club brugge

LIVE: Dan toch 1-1! Club laat zich na penalty Tresoldi te makkelijk vangen, Lautaro zorgt voor gelijkmaker

Filter stories
200+17m ago

rb leipzig

Nach 6:0 in der Liga: Demichelis erwartet anderes Kaliber

Filter stories

Search Results for "FDA Approves MRD-Guided U"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
FDA Approves Signatera CDx as Companion Diagnostic for ctDNA-Guided Adjuvant Atezolizumab in MIBCr
Oncodailygeneral

FDA Approves Signatera CDx as Companion Diagnostic for ctDNA-Guided Adjuvant Atezolizumab in MIBCr

<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTE9WN01ZOVdXTzhZckhFVEI4aG5ITzRmSDd4UU5pSFhDNzNFNEhiYTI3Z0JnQmdVX1ozQmViVmRwYjhqTXg2R09tQkJSVl9NTm5ISEx5X2dfaUExdHVHZ2VNQmFR?oc=5" target="_blank">FDA Approves Signatera CDx as Companion Diagnostic for ctDNA-Guided Adjuvant Atezolizumab in MIBCr</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care
AJMCgeneral

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOQ1VLUzhVNmNjRmZaYndlYkFUSzhWWFpmNVRhSDZrMk93UV83MnplTDFTODl0N0FqTlpjbVRPa3JVQk9NbUZwX1Y4enVnUk43X0FhOWVRUXlIdmdFQTdUT3U5QUhPNW4ycHQ5X19URGZlNl9EdnVsQXhfRnBHNVVaSUswa1ZLbnl2WHJQdVRBcVpJelB2YmJjVW9WMkk0NzdFdjRQb1NB?oc=5" target="_blank">Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer
OncLivegeneral

FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNdU5OYkpmWVZFYmVxa0plRXdfVUF4bnU5b3JmZ1RFYmtfc2ItMXFoWlc4Y3RjeGdwbmFCU3V4SXFHcFlwbUxwNEhRcHNGUFVQTkVMOHcwdm9CSk5mRUI5OEppbE82NTVlWFBoZ0M2Y1ZzREd6R3hIajZHeGpJS2ZoY1Q2cy0tV3I5RDNYRmJMWGtRRjlzcVRBZFI0OFZ5VzhNdU1DLQ?oc=5" target="_blank">FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Adjuvant Atezolizumab for ctDNA MRD–Positive MIBC
Targeted Oncologygeneral

FDA Approves Adjuvant Atezolizumab for ctDNA MRD–Positive MIBC

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPRjZOdW9VVDA1TjYtS3BMb1VOUWtXMTdjMnY1aTNvNER2MGJKSG5HeDhKd2o5VVYwbDVodWJrZlRfNHNkMzJGWDdjUE5EcUNOUGxjRTliZk9aSmN6OVVER0V4LXFwN1dfLU1SRjJxRVNrZDluM0ZVeFhROEI2REtTcl81ZUJhV0dpTlpxSDJRaw?oc=5" target="_blank">FDA Approves Adjuvant Atezolizumab for ctDNA MRD–Positive MIBC</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA approves atezolizumab as adjuvant therapy for MIBC guided by ctDNA
Urology Timesgeneral

FDA approves atezolizumab as adjuvant therapy for MIBC guided by ctDNA

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQOG9hY3M0ZFlVM09WeEtoUUx3cnF0QVUyRlJXbENtUlQ2eVhkYkl0aUUzdTcxSGRyUm80VFZlaWprbmh5R3dfNGljQ2dLYURSZWZIdmJuenR6UEV2dHIxWG81S1cxTXJrVFRIaHJoSDRrWTlhMzZnenpDeVZjWncxcElMR25zN0xJUkJ5bUR0N0lJSTY1SHBySzEydWR2STFEUUZTYjFSSQ?oc=5" target="_blank">FDA approves atezolizumab as adjuvant therapy for MIBC guided by ctDNA</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer
Medscapegeneral

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPNnZMWExWUUNnLWxsdnluR3FfRVFMM1J1MGxKTkhWRDhNS2dxeVNDeXB6dC01YldvMmIzWVVnWm45QzNKTFZMS3JwTjc0VXo5TE9IZ0cyWG5TZDNlZThPUWlKbWpHZDg3OWdRbm1WQ01TX0FVNlhSSWZMNy11eWxBdFg5Qm9pUEVMZEY5TnhkY05NeHBINFZsZGZ2V1BqNGJCZ3JYTG1R?oc=5" target="_blank">FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Bristol Myers Squibbgeneral

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

<a href="https://news.google.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?oc=5" target="_blank">U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse</a>  <font color="#6f6f6f">Bristol Myers Squibb</font>

Read Full StoryMore like this
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
The National Law Reviewtech

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQYVVFdFlmOXF4Yi1OX2JwTmVzeUNPZ0F5bktGdVBHV0tuX2M5eXFIaXN0UWtRSGxTeEM1MlNBSDgxQldQUHN4TEtKaVlLQmZuclBrbUZwWWpjcXByZWZoWWh2dVR1Y2llcHZXelpGdzJTTkJaRHg4Uk1TdVNMNFZhS3RKSVFjVGNMNFBXUjcyUTJlakI4a3BJTFhhVmlQRVV1SzdhZU5acGhMV1hkX3pNZUdSRQ?oc=5" target="_blank">FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment</a>  <font color="#6f6f6f">The National Law Review</font>

Read Full StoryMore like this
Insurance Denials for MRD Tests Plague Patients Amid Soaring Demand
Genome Webgeneral

Insurance Denials for MRD Tests Plague Patients Amid Soaring Demand

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNZ3VIXzYzcnNGeDBmVXczMGtUdnozWDVickRnVjRrZFZvaUZtLU9JT0dWNHNxQ25Kd09vaktJcTU5Y1RnR3p5X3A1VWZyT2xtcGJRQ0VVVVhmbVBYc2pGN3R1bk15dVBBSEFwQWFrZk5MY1pkaFRnQVFlQXpZQl81RkVibjh0WDRGZnl3TXRabVF5OXJXV196aXNzZ2ZIVzBTQ3NIbA?oc=5" target="_blank">Insurance Denials for MRD Tests Plague Patients Amid Soaring Demand</a>  <font color="#6f6f6f">Genome Web</font>

Read Full StoryMore like this
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase-fihj for Relapsed/Refractory Multiple Myeloma
Pharmacy Timesgeneral

FDA Approves Teclistamab Plus Daratumumab Hyaluronidase-fihj for Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPLTh4SV83Qm1ONlBQQWZwZS04M2wzUkJRVk5FenRudW9ONFYxaHZ5MWozcTdXUXVDaWQ0VUZHTU1yQnl0LVRxVy1JaVRxOU5SNFBGeXBtS0RiX3VQb2g4YnNLeGdCM3ROTXRYYzRhdVhJQUhhUG9fS1lmcDJoc3E3OUp5elV1YTdFc21fb3BLRk13Q1RTS2hETXVuTk82QlhBNERaQUxjRG93YVF6eXNlZjV2aS14NDIyc0JYVHN2XzFzTS1PTVk5UkhvQXNPTFNfVlE?oc=5" target="_blank">FDA Approves Teclistamab Plus Daratumumab Hyaluronidase-fihj for Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Developing Clinical Complete Response Definitions for Muscle-Invasive Bladder Cancer
ASCO Daily Newsgeneral

Developing Clinical Complete Response Definitions for Muscle-Invasive Bladder Cancer

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNbmlSVVpYYV83MHoyWFNnanJRdlNlQUZCRzRVR3k5bi10ZjV6QVkta04xVGJ4QVlwWGVYbWtjRHhPWHJyU1Btb0syZEgwcEpORVZuaVBua2M2UlYzNlQ2b1dlYnd0b2VRZ2NJVVQwb1Z5QnEzRXBTYzlwRzluNWxmX0dZV1ZLcVpLX201ZzRfenhENlFBQXpSMzRlNmJWMnNOc1JlaVlVeG11c3JSQ00tLWo0Ym4?oc=5" target="_blank">Developing Clinical Complete Response Definitions for Muscle-Invasive Bladder Cancer</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
First-line treatment for CLL in the era of targeted therapy - Blood Cancer Journal
Naturegeneral

First-line treatment for CLL in the era of targeted therapy - Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBEci1jdEl6bUliOXZEa2hSRW42U09OSnNTZ2toR2xqVjlBLXdIeEQ1cWMwXzRwUktLNmdaTGlhXzY1WTFqcUR1Ung2d2ItZE11UXloU0ZUQlZqai1XaGl3?oc=5" target="_blank">First-line treatment for CLL in the era of targeted therapy - Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Webinar: Making Sense of ctDNA Tests and What They Mean for Colorectal Cancer Care
news.cancerconnect.comgeneral

Webinar: Making Sense of ctDNA Tests and What They Mean for Colorectal Cancer Care

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPYVJxVFRRNUx1Ti03bjE0cmRFVFZET3JEYkthNFlxdVRRU0ZjZVU5ZktLMTM4LURfdm9NVTR5NTZZMzAzV3NvSjhpMEdORDBqWVU3OWl5ZlVmb3FPWFBkTVlfWFRvVVllX3ZNUVJIX29aNnFJbGktc2stQzZiUGJ4WTRGLXRsbTBybmtlZHNXa2U4aF91TXpyYzhubjZDSGVvekRzYTNDRVF4ak41RGR4dU1BOA?oc=5" target="_blank">Webinar: Making Sense of ctDNA Tests and What They Mean for Colorectal Cancer Care</a>  <font color="#6f6f6f">news.cancerconnect.com</font>

Read Full StoryMore like this
NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care
Targeted Oncologygeneral

NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQaWtqYVJOVGVzcFAxUzBQTk9xTE5zeFlvMm56UTBDcExCVUtFRUN0Z2N6dkt1TjByamI2TkcwLXFobGdmRE4ta2FwUWFsNFVSZDRjV1N1RmZoV05rTzFiZVltRnRlWnphQU1RU2RLRUkyQnVKdXpDaFRQVm96MS0wX3BWRHp6QzF0NkNGeG1ETHlxXzQ?oc=5" target="_blank">NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
2025 year in review: Breakthroughs in urologic oncology during a year of unprecedented awareness
Urology Timesworld

2025 year in review: Breakthroughs in urologic oncology during a year of unprecedented awareness

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOMUFDWVBSVHFyQWMtbS1uNy1Ba3B2NmljSDB0cjVMU04zc3ZGZEg4ZWd1VVc2OGNhSFIzUk9tTUFWUjBGNzZxQjBtSTZKeGJsRWJRNWVybFZmU0VWQnlTX09JQjl3d1RkSFFNUS1rN2JJSTNmZ3VLaFpqT0p5WEducVA0QU1aZVV4M1dGaVV5RmVsUW9YSHBwVnRCT00tdHZXa205dUFiVjFuNTNqejZFMDdOeWtybG9XalBndTdSYU50NjVaSzFaXw?oc=5" target="_blank">2025 year in review: Breakthroughs in urologic oncology during a year of unprecedented awareness</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
The Future of MRD in Breast Cancer Treatment
Targeted Oncologygeneral

The Future of MRD in Breast Cancer Treatment

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNdjRCWDNmY2tIYzFxMm5Xb2hQY2hoMjFRTTlSemdUdUE0dm9yTlhHaDZkNmE1ZERuQjZZRHQwOXpGanlUSEVYRUdYd3Zma2QwNndWY3o1UmNkLWtuZVBlU2FwNDR0NWlNTkxVNXUzYWR1M2Jsc0R6aWdDelAtYVVvb0V0Yw?oc=5" target="_blank">The Future of MRD in Breast Cancer Treatment</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer
Natureworld

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE11SXRoa2lGNDZSYVF2SlpJRmh0c1B6WEJBV0RSektXRGNQMkI4RlpCNGhXekMtSlNISldUSnVSYmxHRFI5cGJsQzEySVZnRnFWa1p0TmVaVE9qVXdZcFpr?oc=5" target="_blank">A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
BioSpacetech

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOb3VUa0ZCWWwxOVgzZ3RLVWdMaVJ5NUsxdFNja2dzbVRISFl2QnZRSEFrVFYxcUgtWmpDTWJSUTVwS2tZcVhuZnhNaDVzQ1VsSXJ4S1ZwQkFmOEZjNVpYaHZiNDdxUE5IREZlNW5yV0NuSHVranZtTk1WWFdXcTBFa042ZXR4N1R1Mk14UXVtVi1vMnQ2YkF1dkVNTUxZUjgzN3lqbHFqY0lfdWdsSmhYd1MxVnBEWklFYXhSTHZLaVBTYkJ3SXowQ0N6c0ZOeVE0V2xvOC1mRnVuLW1f?oc=5" target="_blank">NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Shaping Guidelines to Emerging Data—Future Roles of MRD Status and Patient Consideration
OncLivegeneral

Shaping Guidelines to Emerging Data—Future Roles of MRD Status and Patient Consideration

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQX1BNSG94X2xDa0phQVh6blVwWGhuNGc5cWtjY1pzNWR0U3N1ZWxnRGRaZnVHWVlkTGRnQlJ3NDNnMjBpRHM2cjJiVzNQNFRBblJHeUNJLVVXRXdkd2dJMmg5NUxBcE9zVXJTaVJfckE3OXJiQy13bHBQb2dZUWJ6Ym1OMUZaRUpFTm8wQTRlTEpVSnp5dUFYcXZWQ0JvYURBMVNXeWZjdWtxY0Z6SXFjSFFEczZocndh?oc=5" target="_blank">Shaping Guidelines to Emerging Data—Future Roles of MRD Status and Patient Consideration</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers
AJMCgeneral

Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNX3Vzdk14MklMS2s5a0lxT0dHLXFPSWd1WUdvdlk1MjQwQU16WmxxbXpaU2VNbkZjVlg3Ni1kMTdIS2tWR1B6a3FmMmo1WFpOVnFuOXREY2hUTnZLYlFsSG8zUno2ZXp1MklGMGJqVGVITmFKS2tnUXdNSkE2S01MNFg5TV9oY2NPTlAtcU9ZbjN4aURZREs3eA?oc=5" target="_blank">Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
Targeted Oncologygeneral

FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPcl9YRmx5cGNFRGdZWHlrRHZFNnpBNk1SVjVKTENfQVFuY0V5X1dJTXJEUTB5QVhJU2h3RUFyaVdtdjRLcWpqeWNKRHZaSld4aW8tSFI5WVFQa2MyOXZXSk1CNENWU0dnVTlCMXYxTXB3aDExWVlxNkV2YnF1Y0RWb0pXQQ?oc=5" target="_blank">FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
A new drug development paradigm: Treating cancer before radiographic relapse
STATgeneral

A new drug development paradigm: Treating cancer before radiographic relapse

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQMFpfOTR6VDc1dWZMX3NRN3lpalJIU1d5ZjE4ZEs4REQ2QzJSLWxOT182emVHR0duYnZmd1R4STZ5U3BLR1RFYXBTS3FsVUJiYWQtdXNPUlI0RUxocDFiWFJIVDBhSXF4UWh6WC1zZ09yaG8yUFJhOXhLcW1POUNXTU9vWnRocDNFbnI1dlZSbnctMVI0Y21qSkpwdzV3Nmd6YktMYXdDT20zb1BNRjhGNWlhU0NjMVM0OVNBcA?oc=5" target="_blank">A new drug development paradigm: Treating cancer before radiographic relapse</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL
Targeted Oncologygeneral

Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPeVJTdWJrNGZVdmQ5Qk1UOHRBdVRuSWRPSktNOXJJbGR3blNjYlBlRlk3UTI4NEZIME4xcXdKMnpWSzJ1aUdfWDcxYVZ5LTJjV1otS3hERzZhdTJTdlRnYkwySHVEVnJLeEFSTE1KWFB3S2ZmblZuRnpXOHhKTHhiaFcwd3dGX01hZXNNcTJqX01IUkdnTGNKOWNzUU8wZWJIQmlF?oc=5" target="_blank">Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Beyond the Regulatory Landscape and Into Clinical Care: Minimal Residual Disease in Multiple Myeloma Trials and Treatment
ASCO Daily Newsgeneral

Beyond the Regulatory Landscape and Into Clinical Care: Minimal Residual Disease in Multiple Myeloma Trials and Treatment

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPN1RNVTR0MXBOUmxyeXNJZUJqSDFfLTFpRi1wbG5SR0lEN3VuU012aVgyRVF0WjhBVGlrUFU1RUtDZmZ0dFhBX3FTUzRwSjBlVG1zWEFYa01Vc0VEelp4N3pKb3k3cFQ1QjFwaDQ1UHJZOGpLcmlMQjc0cVF3NUFIdW84alBUTjlrWEhJNnhmN1RtWnBSa1lneklUWkRWQThyNWN0QVVpeDc0RHM0X0ZSMHN3czk5dVRxZnc?oc=5" target="_blank">Beyond the Regulatory Landscape and Into Clinical Care: Minimal Residual Disease in Multiple Myeloma Trials and Treatment</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Acalabrutinib Plus Bendamustine and Rituximab Receives FDA Approval in MCL
Targeted Oncologygeneral

Acalabrutinib Plus Bendamustine and Rituximab Receives FDA Approval in MCL

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNMTVmN2d4cW9ueDk2NXdwZ1RpMzJjbHRGdWdqMGxYMnNpLVlJMTRlcXI5YlhfTTBXZ1IzMmx6SEZZQjhUaUlVN1lSM2FRY0VxTXVWbC0xcVgzZnpxLXJZbjBFcm5QTnVsT3FGNnkxZW9lSTROTy1vWXhGNzRYd3JaV1BHdUI5Y3RoYUtqdTJfTGx0QnNBbDlaeHpDbElDT0FSY3Z1T3RrNVJZWHM?oc=5" target="_blank">Acalabrutinib Plus Bendamustine and Rituximab Receives FDA Approval in MCL</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
The ALPHA3 Trial: Next-Gen CAR T and MRD Testing in LBCL
Inside Precision Medicinegeneral

The ALPHA3 Trial: Next-Gen CAR T and MRD Testing in LBCL

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN1NvOFViY2FnYk1sM01JZ2pvdXcyeFdPNUpHREsyVXJSV0VkTDdMLWJNREZKLWF6OUo3anRXLWJtY192VmREN0VFcmsybURfVTB5a0pPMTRsVEpjRUVsckJqVlJyLWlYYml5YTRJMTBHOXpuY2RGV1pFODZjUlRoa0s0bW1pelRvRldmU2NxczlQTmdmSGtoWjlfZHNOUU1DY0t2MHlTQURfQQ?oc=5" target="_blank">The ALPHA3 Trial: Next-Gen CAR T and MRD Testing in LBCL</a>  <font color="#6f6f6f">Inside Precision Medicine</font>

Read Full StoryMore like this
FDA Approves Momelotinib to Treat Myelofibrosis Patients With Anemia
Pharmacy Timesgeneral

FDA Approves Momelotinib to Treat Myelofibrosis Patients With Anemia

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxORFZIVXpaVENES3hWREp1YnBWRDB3anJRZUNMaV9mQ1ZHcjRnTkstV2JJakpYajk5dW9aUnpteHowVVUtSXd0eUJqeFFyVUh0cWo3clQxUVFHTjVmeDVNOVhYRnVvb0Q0QjBoLUgxSHU5cmFwRUFtWUg0dzZRRk1RdHRyV2JVM0l6VG4yQmpBay10bXhwcjd3QnVHRndhdGh0bEZ5X0h3?oc=5" target="_blank">FDA Approves Momelotinib to Treat Myelofibrosis Patients With Anemia</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Pharmacy Timesgeneral

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQemdUWS1UU3k2RUkzYV9WNEVXekxkMlRlR0ZkUXVYVUxHR0NuSnVnZjlHS3lRT3ZGZmN3NG5hODgtVVNxYTRqRVBzNklyQnFXSmlRM0JTaUxhblFDZi1HVVAweVJVXzYtX0wza3FLV0E3ZTc5UlVKejRTWEZUeU5nQXh1S3BoWUJlbFFIM1B2UDc2bnhDUEZxNE12T0kyTmd6TTNTaXlaeVdrdHd3eEplODZoUUQ3QnpNZExCcQ?oc=5" target="_blank">ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions
Targeted Oncologygeneral

Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQS1FVSkpfZlVTVWpuRzVoUE8yNjFUYlJaaUF4bzF1SkRMSUpKZzFKX2M3bm5jR1N6bkROZ1BuQmt1RXJubWxFYjQ1SXJBRFg1enB3MUNoQ2xRcHlFdld0RjhRVkw3dldUNFpzVjBDTEhnRFFkb1duYlE4WXlPdUlRNjVMZGhzaWpDNTE2dmwzX1Fta1FEM3VzaFZiY1lLQnlmdXB2ay1n?oc=5" target="_blank">Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
"FDA Approves MRD-Guided U" — Live Google News Trends & Headlines